Separate analysis of patients with gastric cancer and non–small cell lung cancer showed that all 4 of the analytes (CLGN, TXD15, HSPA5, and RCN1) were significantly increased in patients who developed clots in both gastric and non–small cell cancer cohorts (Figure 1D). This evidence concerns the gene CLGN and lung cancer.